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Running title: MAIT cell development.  
Mucosal-associated-invariant T (MAIT) cells detect microbial vitamin-B2 derivatives 
presented by the antigen-presenting molecule, MR1. Here, we define three developmental 
stages and checkpoints for the MAIT cell lineage in humans and mice. Stage 1 and 2 MAIT 
cells predominate in thymus, while stage 3 cells progressively increase extrathymically. 
Transition through each checkpoint is regulated by MR1 and the final checkpoint that 
generates mature functional MAIT cells is controlled by multiple factors, including the 
transcription factor pro-myelocytic leukemia zinc finger (PLZF) and microbial colonisation. 
Furthermore, stage 3 MAIT cells are expanded in CD1d KO mice, suggesting a niche shared 
between MAIT cells and NKT cells. Accordingly, this study maps the developmental pathway 
and checkpoints that control the generation of functional MAIT cells.  
 
MAIT cells are a specialised T cell lineage that detects microbial vitamin B derivatives presented 
by the major histocompatibility complex (MHC) class I related protein, MR11, 2, 3, 4, 5. Both the 
MAIT TCR and MR1 are highly conserved through evolution suggesting strong selective pressure 
to maintain MAIT cell mediated immunity 6, 7. These cells express a semi-invariant T cell receptor 
(TCR) comprising an invariant TRAV1-2+TRAJ33+ TCR-a chain in humans (TRAV1+TRAJ33+ in 
mice) and a constrained range of TCR-b chains, with a strong bias toward TRBV6 and TRBV20 in 
humans and TRBV19 and TRBV13 in mice. Following activation, MAIT cells rapidly secrete 
cytokines such as IL-17, IFNg and TNF 8, 9, 10, 11 and upregulate Granzymes A and K gaining the 
ability to kill infected target cells12. MAIT cells represent the most abundant antigen-specific T cell 
population in humans, representing, on average, between 5 and 50% of T cells in different human 
tissues, although their numbers can vary widely between individuals 8, 10, 13, 14. Considering their 
functional potency, and a growing number of studies showing that MAIT cells play unique and 
important roles in the immune response to infection with a broad range of pathogens13, 15, 16 and that 
they may also be involved in autoimmunity and other inflammatory responses24, it is important to 
understand how these cells develop.  
 
Previous studies have demonstrated that the development of MAIT cells depends on MR1 
expression in the thymus 1, 4, and that they undergo positive selection and lineage commitment upon 
interaction with MR1-expressing CD4+CD8+ cortical thymocytes17. While phenotypically distinct 
subsets of MAIT cells have been defined in mice and humans including CD4+, CD4-CD8- and CD4-
CD8+ populations 11, 14, the developmental relationship between these different populations is 
unclear and indeed, our understanding of the developmental pathway that leads to the production of 
functionally mature MAIT cells in the thymus and periphery is very limited. In humans, peripheral 
blood MAIT cells express high levels of CD161 and IL-18R and are often defined by the expression 
of TRAV1-2 in conjunction with these markers 8, 9, 18, 19. However, the stage at which these markers 
are acquired during the development of MAIT cells is unclear, so it is difficult to use them to study 
MAIT cell development in the thymus. With the recent development of MR1 tetramers loaded with 
riboflavin derivatives such as 5-OP-RU it is now possible to specifically identify and isolate MAIT 
cells in mice and humans2, 11, 20, 21. Here, we determined the developmental pathway of MAIT cells 
and identify previously undescribed populations of MAIT cells in mice and humans and defined a 3 
stage developmental pathway in both species, defining key control points that control the generation 
of these cells. We also identify several factors including MR1, PLZF, IL-18, Drosha, endogenous 
bacteria and CD1d, that all influence MAIT cell maturation at defined developmental stages. 
 
RESULTS 
Identification of thymic mouse MAIT cell progenitors 
In order to understand MAIT cell development, MR1 5-OP-RU tetramers were used to identify and 
compare these cells and their cell surface phenotype in the thymus and peripheral lymphoid tissues 
of mice. This approach identified a novel population of CD24+CD44- MAIT cells that were 
exclusively present in mouse thymus whereas in peripheral organs essentially all MAIT cells were 
CD24-CD44+ (Figure 1a). To verify that the thymic CD24+CD44- cells were MAIT cells, we 
employed single cell TCR sequence analysis of both CD24+CD44- and CD24-CD44+ populations. 
These data confirmed that both utilized an invariant Va19Ja33 (TRAV1 TRAJ33) TCR-a chain, 
paired with a limited range of TCR-b chains (TRBV13 and TRBV19) (Supplementary Table 1) that 
are characteristic of the MAIT cell lineage 4. Comparison of CD24+CD44- and CD24-CD44+ MAIT 
cells within the thymus revealed sharply contrasting phenotypes (Figure 1b and Supplementary 
Table 2). CD24+CD44- MAIT cells expressed low levels of CD103, CD122 (IL-2Rβ), CD127 (IL-
7Rα), CD218 (IL-18R), CD278 (ICOS) and NK1.1 (CD161c), but higher levels of CD62L and 
CD69 compared to CD24-CD44+ MAIT cells (Figure 1b). Further examination of MAIT cells that 
were enriched from thymus using MR1-5-OP-RU tetramer and magnetic beads revealed an 
additional subpopulation of CD24-CD44- MAIT cells (Figure 1c). Thus, based on their cell surface 
phenotype, we tentatively defined these populations as stage 1 (CD24+CD44-), stage 2 (CD24-
CD44-) and stage 3 (CD24-CD44+) MAIT cells (Figure 1c). Analysis of forward scatter (FSC), CD4 
and CD8 expression on these thymic MAIT cell populations showed that the vast majority of stage 
1 MAIT cells were small (FSClow) and CD4+ or CD4+CD8+, a phenotype that is typically associated 
with immature cells in the thymus and that also defines the earliest stage in the development of 
CD1d-restricted Natural Killer T (NKT) cells 22. Stage 2 cells were larger, mostly CD4+CD8-, 
whereas stage 3 MAIT cells were the largest and resemble mature MAIT cells in peripheral organs, 
being mostly CD4-CD8- or CD8+ (Figure 1a and c). Collectively, our data supports the presence of 
at least three distinct stages of MAIT cell development within mouse thymus.  
 
Functionally mature stage 3 MAIT cells arise through ontogeny  
To investigate the developmental progression of the three subsets of thymic MAIT cells, we carried 
out an ontogeny study for MAIT cell subsets in mouse thymus at 2, 4 and 8 weeks of age. Stage 1 
MAIT cells were the major subset (>50%) in the very young mouse thymus at 2 weeks, declining to 
~30% at 4 weeks and ~10% of total thymic MAIT cells in the adult 8-week-old mouse thymus 
(Figure 2a and b). Conversely, the proportion of stage 3 MAIT cells was low (~20%) at 2 weeks 
and gradually increased with age (~60% at 4 weeks and ~80% at 8 weeks) (Figure 2a and b), 
supporting the developmental progression of MAIT cells from stage 1 to stage 3.  
 
To determine at which stage MAIT cells gain functional maturity, we first examined the three 
maturation stages for the expression of transcription factors known to regulate cytokine production 
in MAIT cells. Stage 1 and 2 cells expressed low levels of RORgT and T-bet suggesting these cells 
would have limited capacity to secrete the cytokines IL-17 and IFN-g that are produced by mature 
mouse MAIT cells11 (Figure 2c). In contrast, stage 3 MAIT cells expressed either RORgT or T-bet 
(but not both) suggesting that these cells are likely to be functionally competent (Figure 2c and data 
not shown). Analysis of RORgT-GFP reporter mice confirmed that only stage 3 cells expressed 
GFP (Supplementary Figure 2). To verify that RORgT and T-bet expression correlated with the 
ability of MAIT cells to produce cytokines, thymic MAIT cells were tested for IL-17 and IFN-g 
following mitogenic stimulation. Consistent with the transcription factor expression pattern, only 
the most mature, stage 3 MAIT cells were capable of cytokine production in this assay (Figure 2d). 
Accordingly, the loss of CD24 and the acquisition of CD44 correlates with the expression of 
RORgT and T-bet and the acquisition of functional potential of mouse MAIT cells.  
 
Precursor-product relationship of mouse MAIT cell subsets 
To directly investigate the precursor/progeny relationship of the three stages of thymic MAIT cells 
that we have identified, we established an in vitro MAIT cell development system, using an 
adaptation of the OP9 cell-thymocyte co-culture system23. Because the numbers of thymus MAIT 
cell subsets in wild type mice are very low, we initially used Va19 TCR transgenic Ca-/- mice 
where the thymus MAIT cells, including the three different stages defined above, were far more 
abundant (Supplementary Figure 1), thus allowing us to isolate sufficient numbers of these cells for 
in vitro differentiation studies. After 5 days of co-culture with OP9 cells, purified stage 1 MAIT 
cells had started to differentiate into stage 2 and stage 3 cells (Figure 3a and b). Similarly, the stage 
2 cells had progressed further toward stage 3, whereas the stage 3 cells maintained their mature 
CD24-CD44+ phenotype (Figure 3a and b). Importantly, MAIT cell differentiation in these cultures 
was dependent on the presence of OP9 cells, indicating the importance of stromal cell-derived 
factors in the MAIT cell differentiation process. In this assay, we also tested OP9 cells engineered 
to express the Notch ligand, Delta-like 1, (OP9-DL1) and found that signalling through DL1 was 
not required for maturation of TCR+ MAIT cell precursors (data not shown) similar to the 
maturation of gd T cells from gdTCR-expressing T cell precursors 24. Hence, parental OP9 cells 
were used for subsequent experiments. The presence of anti-MR1 blocking antibody completely 
inhibited the progression of stage 1 to stage 3 MAIT cells, and partially inhibited the differentiation 
or survival of stage 2 and stage 3 cells, as reflected by a sharp reduction in cell numbers by the end 
of culture (Figure 3a and b). These data are consistent with the lack of MAIT cells in MR1-deficient 
mice 1, 11, 14, but also highlight that the expression of MR1 is critical for both the initial development 
and further differentiation and/or survival of MAIT cells. 
 
Having established this differentiation sequence using Va19 TCR transgenic MAIT cells, we next 
undertook similar experiments using MAIT cell subsets from wild type mice (Figure 4a and b). 
Because these cells were much less frequent, we were unable to isolate sufficient numbers of the 
intermediate stage 2 cells, but nonetheless, the results of culturing stage 1 and stage 3 MAIT cells 
matched those observed with the Va19 TCR transgenic cells (Figure 3a and b). Thus, stage 1 cells 
progressed to stages 2 and 3 after 5 days of co-culture with OP9 cells, whereas stage 3 cells 
maintained their mature phenotype. Taken together, these data confirm that differentiation of mouse 
MAIT cells can be defined by a three-stage sequential pathway from CD24+CD44- (stage 1), via 
CD24-CD44- (stage 2), to CD24-CD44+ (stage 3).  
 
PLZF controls the maturation and function of MAIT cells 
The transcription factor PLZF, known to be important for the development of NKT cells, ILC cells 
and some gd T cells 25, 26, 27, 28 is expressed by MAIT cells in humans and mice 11, 14. We recently 
determined that the production of normal numbers of MAIT cells depends upon this factor, 
although notably, a residual population of MAIT cells remained in PLZF-deficient mice 11. Using 
wild type mice, we determined that this transcription factor is first expressed on stage 2 MAIT cells, 
which were heterogeneous for PLZF expression, and fully expressed by stage 3 (Figure 4a). 
Examination of PLZF null mice revealed that the stage 1 and stage 2 MAIT cell compartments were 
intact, whereas stage 3 MAIT cells were completely absent (Figure 4b and c). Even in peripheral 
tissues, the residual MAIT cells were also blocked at stage 2 including a predominantly CD4+CD8- 
phenotype (Figure 4b), and lack of CD218, CD127 and CD103 expression (data not shown), thus 
resembling immature MAIT cells as shown in (Figure 1b). In addition, stimulation of the residual 
MAIT cells from the thymus, spleen and lymph nodes from PLZF KO mice failed to yield 
cytokines compared to wild type controls, which expressed either IL-17A or IFN-g (Figure 4d). 
This suggests that the progression to stage 2 is PLZF independent but maturation of stage 2 to stage 
3 and importantly the acquisition of function is absolutely dependent on PLZF, and furthermore this 
can occur after stage 2 cells leave the thymus. In the absence of the PLZF driven maturation signal, 
stage 2 MAIT cells remain immature in both thymus and peripheral tissues. 
 
Drosha controls the development of MAIT cells 
MicroRNAs (miRNAs) play important roles in regulating gene expression and profoundly influence 
cell differentiation, development and function of NKT cells 29 so we sought to examine if these 
were also important in MAIT cell development. We examined the role of Drosha, a member of the 
ribonuclease III superfamily that initiates miRNA processing in the nucleus 30, in the development 
of MAIT cells using Drosha CD4-cre mice, which have a marked reduction in the level of Drosha 
in CD4+ CD8+ thymocytes 31. Drosha deficiency resulted in a drastic reduction in MAIT cell 
development in the thymus. However, unlike PLZF null mice, which display an accumulation at 
stage 2 (CD44- CD24-) and a complete block in the transition to stage 3 (CD24-CD44+), Drosha 
CD4-cre mice contained all three developmental stages of thymic MAIT cells, yet the numbers of 
stage 2 (CD24-CD44-) and, more so, stage 3 (CD24-CD44+) MAIT cells were both significantly 
reduced in these mice compared to wild type controls (Figure 5a and b). Indeed, the vast majority of 
MAIT cells in the thymus of Drosha CD4-cre mice exhibited an immature stage 1 CD24+ CD44- 
phenotype (Figure 5a). This suggests that the transition from stage 1 to stage 2 and beyond is 
dependent on Drosha. Despite the impaired development of MAIT cells in the thymus of Drosha 
CD4-cre mice, stage 3 CD44+ MAIT cells were still detected in the spleen and lymph nodes of 
these mice albeit at greatly reduced numbers compared to wild type controls (Figure 5a and b). 
Given that previous studies have shown a role for miRNA in the development of NKT cells, using 
mice lacking Dicer, another member of the ribonuclease III superfamily32, we also examined 
whether NKT cells were depleted in Drosha CD4-cre mice. We observed a significant reduction in 
NKT cells within the thymus, spleen and lymph nodes of these mice (Figure 5a and c), which is 
consistent with earlier studies of Dicer deficient mice. Accordingly, these data indicate that Drosha 
controls the development of MAIT cells, and it impacts on a different stage of MAIT cell 
development compared to PLZF. 
 
MAIT cell development is impaired in germ-free mice 
Given that a previous study reported that MAIT cells are absent in germ-free mice 1, we wanted to 
examine which stage of MAIT cell development was impaired in these mice. We found that MAIT 
cells were present in the thymus of germ-free mice, although their numbers were significantly 
reduced compared to control mice (Figure 5d and e). Moreover, there was a significant decrease in 
thymic stage 3 CD44+ MAIT cells (Figure 5d), while stage 1 CD24-CD44- MAIT cells were 
increased in frequency but not number (Figure 6d and not shown). Reduced but detectable numbers 
of MAIT cells were also observed in the spleens and lymph nodes of germ-free mice compared to 
control mice (Figure 5d and e). Thus, while MAIT cells were not completely absent in germ-free 
mice, their development was drastically impaired resulting in fewer MAIT cells in both the thymus 
and periphery. In sharp contrast, no difference was observed in NKT cell numbers or percentages 
from germ-free mice (Figure 5d and f) suggesting that commensal flora is required for efficient 
MAIT cell development but not for NKT cell development. 
  
Given that the level of IL-18 is diminished in germ-free mice 33 and that MAIT cells express IL-
18R during their maturation in the thymus (Figure 1), we examined whether the loss of IL-18 would 
impact on MAIT cell development. Similar to germ-free mice, IL-18 KO mice displayed an overall 
reduction in MAIT cell numbers and a decrease in the frequency of thymic stage 3 CD24-CD44+ 
MAIT cells, with an increase in the frequency but not number of stage 1 CD24-CD44- MAIT cells 
(Supplementary Figure 3a and b). Furthermore, MAIT cells were also significantly reduced in the 
spleen and lymph nodes of IL-18 deficient mice (Supplementary Figure 3a). Considering that this 
defect was similar to that observed in PLZF null mice, we examined PLZF deficient MAIT cells for 
IL-18R express and found that these cells completely lack expression of this receptor 
(Supplementary Figure 3g). To further investigate the significance of IL-18, we next examined the 
importance of IL-18R signalling in MAIT cell development, using IL-18R deficient mice. 
Unexpectedly, IL-18Ra KO mice showed normal MAIT cell development and maturation within 
the thymus, spleen and lymph nodes (Supplementary Figure 3c and d). In contrast, the numbers of 
NKT cells these mice were markedly reduced in the thymus (Supplementary Figure 3e and f), 
suggesting signalling through this receptor is important for the development of NKT cells but not 
MAIT cells. This represents a striking difference in the regulation of MAIT cell versus NKT cell 
development, but is difficult to understand given the defect in MAIT cell development in IL-18 
deficient mice. Another cytokine, IL-37, can also signal through the IL-18R (ref), which might 
complicate the comparison of IL-18 and IL-18R deficient mice, so we also tested MAIT cell 
development in IL-37 overexpressing transgenic mice but found that this process was largely 
normal in these mice (data not shown).  
 
Thus, MAIT cell development and maturation is impaired in germ free mice, reflecting an 
important role for endogenous bacteria in this process, but it is currently unclear whether reduced 
IL-18 production plays a role in this process. Regardless, it is possible that other microbial induced 
factors not limited to IL-18 might be important for MAIT cell development.  
 
MAIT cell development is normal in B cell deficient µMT mice  
B cells have previously been implicated as regulators of MAIT cell maturation or homeostasis 1, 14, 
although the precise impact on this process is unclear. Therefore, we examined MAIT cell 
development and maturation in B cell deficient µMT mice, in the context of the three-stage 
development pathway we have identified. Consistent with observations from Va19 TCR transgenic 
mice 1, 14, we found no change in MAIT cell numbers in the thymus and furthermore, each of the 
three developmental stages were represented normally when comparing the thymus of µMT mice 
and wild type control mice (Supplementary Figure 4). Furthermore, MAIT cell numbers and subsets 
were also similar in the spleens of µMT and control mice despite the lack of B cells and reduced 
size of the spleens of µMT mice (Supplementary Figure 4). In contrast, analysis of inguinal lymph 
node showed a clear reduction of MAIT cell numbers in µMT mice compared to wild type controls 
(Supplementary Figure 4) and this primarily impacted on the CD4+ MAIT cell population (data not 
shown), which we have previously shown are more abundant in lymph nodes 11. These data indicate 
that MAIT cell development and maturation is broadly normal in B cell deficient mice, although B 
cells maybe required for population or expansion of a subset of MAIT cells in some but not all 
peripheral organs.  
 
MAIT cells are over-represented in CD1d deficient mice 
In order to investigate whether there were any associations between NKT cells and MAIT cells 
during intrathymic development, we also examined MAIT cells in CD1d knockout mice that lack 
both CD1d and CD1d-restricted NKT cells. Both BALB/c and C57BL/6 CD1d knockout mice were 
examined for these studies, which unexpectedly showed increased numbers of MAIT cells in 
thymus, spleen (Figure 6a and b) and liver (not shown) compared to wild type controls on both 
strain backgrounds, and this was particularly apparent on the BALB/c background (Figure 6a and b). 
Moreover, analysis of the three MAIT cell developmental stages within the thymus revealed that 
stage 1 and 2 MAIT cells were unchanged and the increase was first apparent in the mature stage 3 
CD24-CD44+ MAIT cell population in CD1d KO mice (Figure 6a and b). Taken together, these data 
suggest that MAIT cells and NKT cells may compete for some of the same factors during their final 
maturation in the thymus and that this translates to an increase in mature MAIT cells in the 
periphery.  
 
Identification of MAIT cell precursors in human thymus. 
We next determined whether MAIT cell development in humans follows a similar developmental 
pathway to that of mice. We compared MAIT cells in human thymus, cord blood, young blood 
(matched to thymus donors) and adult blood, using human MR1-5-OP-RU tetramers in combination 
with other markers commonly used to identify MAIT cells including TRAV1-2, CD161 and CD218 
(IL-18R) 8, 9, 18. MAIT cells (defined as TRAV1-2+ MR1-5-OP-RU tetramer+) were detected in all 
human thymus samples, although they were much less frequent (<0.05%) than in adult human 
blood where they typically represent 2-5% of CD3+ T cells 11. Because they were so infrequent in 
human thymus, TRAV1-2+ cells were first enriched using magnetic beads, which then yielded a 
clear population of MAIT cells, ranging from 0.08-0.45% of TRAV1-2+ thymocytes (Figure 7a and 
b). The frequency of MAIT cells as a percentage of TRAV1-2+ cells increased in cord blood, young 
blood and adult blood suggesting that peripheral expansion is responsible for the majority of MAIT 
cells in humans.  
 
Human thymic MAIT cells were phenotypically distinct from MAIT cells in blood. The vast 
majority of MAIT cells from peripheral blood of adult co-expressed CD218 and CD161 while, in 
stark contrast, most (up to 97%) thymic MAIT cells were CD218-CD161- (Figure 7a and b). Even 
in young blood and cord blood, the majority of MAIT cells were CD218+ and CD161+. Thus, 
CD218-CD161- MAIT cells are predominant in human thymus and gradually diminished in 
frequency in increasingly mature peripheral blood samples, suggesting that these cells are immature 
precursors (Figure 7a and c). Furthermore, whereas blood MAIT cells were predominantly CD4-
CD8- or CD4-CD8+ (Figure 7a) consistent with previous reports 8, 9, 14, 21, roughly half of thymus 
MAIT cells were either CD4+CD8+ or CD4+CD8- (Figure 7a). Moreover, analysis of paired thymus 
and blood samples showed that CD4+ MAIT cell populations declined sharply between thymus and 
matched blood samples (Figure 7d). 
 
Because we have sampled human thymuses and matched blood samples from ages ranging from 5 
days to 14 years, we were able to undertake an ontogeny study of matched thymus and blood 
samples. This demonstrated that MAIT cell frequencies (as a percentage of TRAV1-2+ cells) 
remain relatively low and stable in the thymus (0.1-0.3% of TRAV1-2+ cells) regardless of age 
(Figure 7e) whereas their frequency gradually increased in peripheral blood from less than 1% to up 
to 60% of TRAV1-2+ cells with age (Figure 7e). Thus, the characteristically high numbers of MAIT 
cells in human blood is a result of gradual peripheral expansion with age. 
 
CD161- MAIT cells in the thymus could be further divided based on CD27 expression, and of these, 
the CD161-CD27- subset was exclusively found in thymus, whereas CD161-CD27+ were detected at 
low frequency in cord blood (~22%) and young blood (~13%) and were essentially absent from 
adult blood (~1%). Conversely, CD161+CD27+/lo MAIT cells were rare in thymus (~10%) and 
abundant in blood (Figure 7a and f). Thus, we tentatively defined three distinct stages of MAIT cell 
development in human thymus; being stage 1 (CD161-CD27-); stage 2 (CD161-CD27+) and stage 3 
(CD161+CD27+/lo). Further analysis of these stages demonstrated the decline in stage 1 and 2 and 
the rise in stage 3, with increasingly mature human compartments (Figure 7a and f). In line with this 
maturation pathway, stage 1 MAIT cells were predominantly CD4+CD8+, stage 2 MAIT cells were 
included both CD4+, CD4+CD8+ cells, and CD4-CD8+ cells whereas stage 3 MAIT cells were 
mostly CD4-CD8- or CD8+ (Figure 7a and c), more closely resembling MAIT cells found in human 
peripheral blood (Figure 7a and c).  
 
Many peripheral CD8+ MAIT cells express CD8αα homodimers rather than CD8αβ heterodimers 9. 
Given that most human thymocyte express CD8ab heterodimers we sought to determine where in 
the three-stage development pathway human MAIT cells began to express CD8aa homodimers. 
Essentially all CD8+ MAIT cells in the human thymus expressed the CD8αβ heterodimer, 
regardless of whether they were at stage 1, 2 or 3 of development (Figure 8a). However in blood 
samples, including thymus matched blood samples, a high proportion of MAIT cells were CD8αα+ 
(Figure 8a). This distinct dimer profile of thymic MAITs is consistent with earlier reports 
suggesting that CD8αα MAIT cells develop from a pool of CD161+CD8αβ T cells 9, 19. Furthermore, 
this also strongly suggests that the stage 3 MAIT cells in human thymus were not recirculating cells 
from the periphery.  
 
We next examined the expression of chemokine receptors CCR5 and CCR6, both associated with 
migration to the peripheral lymphoid organs 34. The majority of stage 1 and stage 2 cells in the 
thymus did not express CCR5 or CCR6, but these receptors were upregulated at stage 3 (Figure 8a), 
supporting the concept that stage 3 cells are the most mature cells that can emigrating from the 
thymus. These CD161+ stage 3 cells remained CCR5+ in the peripheral blood and a proportion of 
them downregulated CCR6 (Figure 8a). (MAIT cells are known to express tissue homing 
chemokine receptors9, 35  
 
Functional maturation begins at stage 3 in MAIT cell development 
Similar to the transcription factor profiling of mouse MAIT cells (Figure 2c), the 3 stages of human 
thymic MAIT cells were examined for expression of the transcription factors PLZF, RORγT and T-
bet. PLZF and T-bet were initially upregulated at stage 2, and highly expressed at stage 3 (Figure 
8b). RORγT showed a similar pattern with highest expression at stage 3, although a small subset of 
stage 1 MAIT cells also expressed this molecule, which likely reflects the recent transition of these 
cells from CD4+CD8+ cortical thymocyte precursors that are RORgt+ (Figure 8b). Collectively, the 
transcription factor profile of human stage 3 MAIT cells resembled those in human blood (Figure 
8b) and also closely paralleled stage 3 MAIT cells from mice. 
 
To directly test these cells for functional competence, human thymic and matched blood MAIT 
cells were activated and examined for cytokine production (IFN-g, TNF and IL-17) (Figure 8c). 
While a subset (<25%) of stage 3 thymic MAIT cells were capable of producing IFN-g and TNF at 
moderate levels, the matched blood stage 3 cells were far superior in their cytokine producing 
potential with the majority (>80%) of these cells producing both IFN-g and TNF. We were unable 
to detect IL-17 production in these assays, which may reflect the need for additional stimulatory 
factors such as IL-7, as previously reported for human MAIT cells 10. 
 
DISCUSSION 
In this study, using MR1-5-OP-RU tetramers, we have identified precursor populations for the 
MAIT cell lineage in the thymus and mapped a three-stage pathway in both mice and humans 
(Supplementary Figure 5). In mice, MAIT cells develop in a stepwise pathway from CD24+CD44- 
(stage 1, thymus only), via CD24-CD44- (stage 2, mainly thymus), to CD24-CD44+ (stage 3, thymus 
and mainly periphery). In humans, a similar pathway proceeds from least mature CD161-CD27- 
(stage 1, thymus only) MAIT cells, via CD161-CD27- (stage 2, mainly thymus), to CD161+CD27+/- 
(stage 3, mainly periphery) cells. Only stage 3 cells are capable of producing cytokines and these 
resemble MAIT cells in peripheral organs, although further extrathymic maturation occurred for 
human stage 3 cells. Based on the presence of some stage 2 cells in human blood, especially in cord 
blood, and also in PLZF deficient mice where MAIT cells are detected in the periphery but blocked 
at stage 2, it seems that MAIT cells can first emigrate from the thymus at this stage and continue 
their maturation and expansion extrathymically. This human differentiation pathway for MAIT cells 
is reminiscent of human CD1d-restricted NKT cells, which also undergo their final maturation 
(upregulation of CD161 and downregulation of CD4) extrathymically 36. 
 
Our data provide a very different perspective of MAIT cell development to that of previous studies 
that relied on surrogate phenotypic markers such as CD161 and Va7.2 to identify MAIT cells in 
humans 19 or the use of transgenic TCR systems or ROR-gt to detect MAIT cells in mice 14, 37, 38. As 
we have now determined, the surrogate markers for human MAIT cells, including CD161 and 
CD218, will exclude immature MAIT cells that lack these markers. In the earlier mouse studies, the 
highly expressed Va19Ja33 transgenic TCR-a chain used in a previous study 14 appears to have 
altered the developmental process resulting in many MAIT TCR+ cells lacking PLZF and CD44, 
which gave the impression that mature mouse MAIT cells exhibit a naïve phenotype in the thymus, 
which is not the case for mature non-transgenic MAIT cells in the thymus. More recently, a new 
approach using ROR-gt-GFP combined with CD44 38 can identify mature stage 3 MAIT cells, 
although may miss those that do not express ROR-gt (Figure 2), but this approach will also have 
missed immature MAIT cells that lack both CD44 and ROR-gt. 
 
We have previously determined that MAIT cells are reduced, but not absent, in PLZF-/- mice 11. 
However, it was not known whether the residual MAIT cells reflected a leaky phenotype in these 
mice, or a separate PLZF-independent subset. Here, with the advantage of our defined 3 stage 
developmental pathway, we were able to show that without PLZF, most MAIT cells are absent 
because of a complete block in development of mature stage 3 cells, whereas stage 1 and 2 are 
unperturbed in the absence of this factor. Thus, this pathway allows us to pinpoint precisely where 
in MAIT cell development is dependent on the PLZF transcription factor, and to show that there is 
an absolute developmental defect in the absence of PLZF and the residual MAIT cells in these mice 
are immature. 
 
There are some similarities between the development of MAIT cells and CD1d-restricted NKT cells. 
Both lineages depend on PLZF expression for normal maturation, and both are dependent on 
miRNA expression regulated by Drosha. Furthermore, both CD24 and CD44 markers are 
sometimes used to define early NKT cell subsets in mice 22, 39. However, there are some important 
differences between the development of these lineages. Firstly, PLZF is expressed at high levels 
very early in NKT cell development and is downregulated in most mature NKT cells26, 28, with the 
exception of the minor subset of IL-4 producing NKT2 cells 40, 41. In contrast, PLZF is expressed in 
late in MAIT cell development, it governs their final maturation step to generate functional stage 3 
MAIT cells and is maintained at high levels by these cells. Also, upon maturation, most NKT cells 
upregulate NK1.1 and CD69 and they are either CD4+ or CD4-CD8-. Conversely, we have shown 
that most mature MAIT cells do not express NK1.1, they down regulate CD69 upon maturation, 
and many express CD8ab heterodimers, particularly in BALB/c mice and humans. In addition, 
MAIT cell maturation is impaired in germ-free mice (Figure 5d and e), whereas NKT cell 
maturation is intact in these mice. Lastly, as previously shown, while the SLAM adaptor protein 
(SAP) is critical for NKT cell development42, MAIT cells appear to be SAP independent14. Thus, 
while there are some parallels between MAIT cell and NKT cell development, there are also some 
important differences. This is perhaps not surprising given their apparent reciprocity in mice and 
humans, where mice have high numbers of NKT cells and low MAIT cells and humans are the 
opposite 43. Furthermore, our unexpected observation that MAIT cells are over-represented in 
CD1d/NKT cell deficient mice suggests that these cells may compete for an environmental niche. 
 
While the developmental sequence for MAIT cells in mice and humans has many parallels, there 
were also some distinctions. In humans, while we were able to detect stage 3 (mature) MAIT cells 
in the thymus, these were in the minority and were only partially functional. Our data suggest that 
human MAIT cell maturation mostly occurs after these cells leave the thymus and begin 
recirculating through the body, with increasing frequency of mature (stage 3) MAIT cells seen from 
cord blood, to young peripheral blood, to adult blood. During this extrathymic maturation of MAIT 
cells, they also acquire greater cytokine producing capacity and many switch from CD8ab to 
CD8aa expressing cells. We hypothesise that this peripheral expansion and maturation may be 
driven by exposure to microbial antigens over time, which is also supported by our studies with 
germ free mice where stage 3 MAIT cells were deficient in thymus and periphery (Figure 7 and 1) 
and also by a recent paper that demonstrated microbial mediated expansion of peripheral MAIT 
cells in a mouse model of Salmonella infection 44. 
 
Having established this three stage developmental pathway for MAIT cells, this should lay the 
foundations for future studies into the antigens that control the intrathymic selection of these cells. 
While it is well established that their development in the thymus depends on MR1 expression by 
CD4+CD8+ thymocytes 17, we have shown here that MR1 expression is also important for their 
continued maturation through each developmental stage. These findings also highlight the 
important question of whether MR1-bound antigens play a key role in positive selection of MAIT 
cells, and if so, what are these antigens? Given that in germ-free mice, MAIT cells developed 
normally up to stage 2, but further maturation and/or expansion at stage 3 was impaired, this 
suggests that endogenous self antigens might regulate the initial control points up to stage 2 and 
microbial-antigens impact on the final stage 3 of this process. This also raises the question of 
whether MAIT cells can undergo negative selection if they encounter agonist antigens, such as 
microbial derived riboflavin derivatives, too early in their development? These will be important 
questions to investigate in future studies of MAIT cell development.  
 
In summary, we have defined thymic precursors for the MAIT cell lineage and mapped a three-
stage developmental pathway for MAIT cell development and maturation in mice and humans that 
is controlled by developmental checkpoints. We have identified some key factors that control this 
process and most importantly, this study will provide a firm basis for future studies to better 
understand the factors that regulate the highly abundant, yet highly variable, MAIT cell lineage.  
 
  
Figure Legends 
Figure 1. Identification of distinct MAIT cell subsets in mouse thymus  
Flow cytometry analysis of MR1-5-OP-RU tetramer reactive MAIT cells for expression of CD24, 
CD44, CD4 and CD8 in adult mouse thymus, spleen, lung and lymph nodes.  MR1-Ac-6-FP 
tetramer was used as a negative control. Data are representative of a total of 6 mice from 3 
independent experiments. (b) Phenotypic analysis of CD24+CD44- and CD24-CD44+ thymic MAIT 
cells with ICOS, CD161 (NK1.1), CD62L, CD69, CD103, CD122 (IL-2R), CD127 (IL-7R) and 
CD218 (IL-18R), CD24+CD44- MAIT cells in blue, CD24-CD44+ MAIT cells in red, CD4+CD8+ 
double positive thymocytes in black. Data from 5 pooled mice from each experiment and is 
representative of 2 independent experiments for each phenotypic marker. (c) Identification of three 
populations of thymic MAIT cells following magnetic bead enrichment. Flow cytometry analysis of 
3 stages of MAIT cells defined using CD24 and CD44. Stage 1 (CD24-CD44+) in blue, stage 2 
(CD24-CD44-) in green and stage 3 (CD24-CD44+) in red. Forward scatter (FSC) and CD4/CD8 co-
receptor expression on stage 1, stage 2 and stage 3 MAIT cells. Data are representative of at least 
10 independent experiments. 
 
Figure 2. Ontogeny, transcriptional and functional potential of mouse MAIT cells 
(a) Thymii from 2 week, 4 week and 8-week old C57BL/6 mice were pooled, enriched for MR1-5-
OP-RU tetramer+ cells and analyzed for CD24 and CD44 expression. Data are representative of 4 
independent samples per age group. (b) Percentages of stage 1, stage 2 and stage 3 MAIT cells in 2 
week, 4 week, and 8-week old mice thymii and the bar depicts the mean ± SEM from 4 independent 
samples. (c) RORγT and Tbet expression on stage 1, stage 2 and stage 3 MAIT cells from enriched 
C57/BL6 wild type (WT) mouse thymus. Data are representative of 3 independent experiments. (d) 
Enriched mouse thymocytes were stimulated for 4h in presence of PMA/ionomycin, labeled with 
MR1-5-OP-RU tetramer and surface antibodies, fixed and permeabilized and then stained with anti-
IFN-γ or IL-17A. Data are representative of 3 independent experiments.  
 
Figure 3. Precursor product relationship of mouse MAIT cells 
(a) CD24-CD44+ MAIT cells develop from stage 1 CD24+CD44- and stage 2 CD24-CD44- 
precursors. Stage 1, stage 2 and stage 3 MAIT cells from Va19 TCR transgenic (TG) mouse thymii, 
and stage 1 and stage 3 MAIT cells from wild type mouse thymii, were purified by flow cytometric 
sorting (day 0) and cultured in the presence or absence of OP9 cells, with or without anti-MR1 
antibody. Cultures were harvested on day 5 and MAIT cells examined for CD24 and CD44 
expression. Data are representative of 3 independent experiments. (b) Percentages and numbers of 
stage 3 MAIT cells at the end of culture. Bars depict mean ± SEM for 3 independent experiments.   
  
Figure 4. PLZF controls development of MAIT cells 
(a) PLZF expression on stage 1, stage 2 and stage 3 cells from enriched C57BL/6 wild type  (WT) 
mouse thymus. (b) Analysis of MAIT cells from spleen, lymph node or enriched thymii from 
C57BL/6 WT and PLZF knockout (KO) mice. Cells were examined for CD24, CD44, and 
CD4/CD8 co-receptor expression using flow cytometry. Data are representative of 3 independent 
experiments with a total of 9 mice per group. (c) Percentages of stage 1, stage 2 and stage 3 MAIT 
cells in enriched thymii, spleen and lymph nodes of WT and PLZF KO mice. Bars depict mean ± 
SEM, data are representative of 3 independent experiments with a combined total of 9 mice per 
group *P<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. (d) Cytokine 
production of MAIT cells from WT and PLZF KO mice. Cells were stimulated for 4h in presence 
of PMA/ionomycin, labeled with MR1-5-OP-RU tetramer and surface antibodies, fixed and 
permeabilized and then stained with anti-IFN-γ or IL-17A. Data are representative of 2 independent 
experiments with a total of 6 mice per group.  
 
Figure 5. MAIT cells fail to develop fully in Drosha KO mice and are almost absent in the 
periphery of Germ Free mice. 
(a) Analysis of MAIT from pooled MR1-5-OP-RU enriched thymii, whole spleen and lymph nodes 
from C57BL/6 WT and Drosha KO (KO) mice. Cells were examined for CD24, CD44 and 
CD4/CD8 co-receptor expression using flow cytometry. Analysis of NKT cells was done on whole 
thymus, spleen and lymph nodes.  Data are representative of 2 independent experiments with a total 
of 6 mice per group. (b) Absolute numbers and percentage CD44+ of MAIT cells recovered per 
thymus post MR1-5-OP-RU enrichment from WT and Drosha KO (KO) mice were graphed. 
Absolute numbers and percentage MAIT cells of TCRβ+ cells in spleen and lymph nodes of WT 
and KO mice were graphed. (c) Absolute numbers and percentage NKT cells of TCRβ+ cells in 
thymus, spleen and lymph nodes of WT and Drosha KO (KO) mice were graphed. Bars depict 
mean ± SEM, data are representative of 2 independent experiments with a combined total of 6 mice 
per group *P<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. (d) Analysis of 
MAIT from pooled MR1-5-OP-RU enriched thymii and whole spleen from C57BL/6 WT and Germ 
Free (GF) mice. Cells were examined for CD24, CD44, and CD4/CD8 co-receptor expression using 
flow cytometry. Analysis of NKT cells was done on whole thymus and spleen.  Data are 
representative of 2 independent experiments with a total of 11-15 mice per group. (e) Absolute 
numbers and percentage CD44+ MAIT cells of TCRβ+ cells recovered per thymus post MR1-5-OP-
RU enrichment from WT and GF mice were graphed. Absolute numbers and percentage MAIT 
cells of TCRβ+ cells in spleen of WT and GF mice were graphed. (f) Absolute numbers and 
percentage NKT cells of TCRβ+ cells in thymus and spleen of WT and GF mice were graphed. Bars 
depict mean ± SEM, data are representative of 2 independent experiments with a combined total of 
11-15 mice per group *P<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. 
 
Figure 6. MAIT cell numbers are increased in CD1d KO mice. 
(a) Analysis of MAIT cells from whole thymus and spleen from BALB/C WT, BALB/C CD1d KO, 
C57BL/6 WT and C57BL/6 CD1d KO mice. Representative plots show analysis from BALB/C WT 
and BALB/C CD1d KO (KO) mice. Cells were examined for CD24, CD44 and CD4/CD8 co-
receptor expression using flow cytometry. Data are representative of 3 independent experiments 
with a total of 6-9 mice per group. (b) Percentages of CD44+ MAIT cells in the individual thymus 
of BALB/C WT, BALB/C CD1d KO, C57BL/6 WT and C57BL/6 CD1d KO mice were graphed in 
the first row. Absolute numbers and percentage of MAIT cells of TCRβ+ cells in individual thymus 
and spleen from these mice were graphed. Bars depict mean ± SEM, data are representative of 3 
independent experiments with a combined total of 6-9 mice per group *P<0.1 **P<0.01 
***P<0.001 using a Mann-Whitney rank sum U test. 
 
Figure 7. Identification of distinct MAIT cell subsets in humans 
(a) Flow cytometric analysis of adult peripheral blood samples, human thymus samples enriched for 
Vα7.2+ cells, young peripheral blood samples matched from the thymus donors, and donor cord 
bloods. The first two panels depict CD3+ lymphocytes, stained with anti-Va7.2 and either MR1-Ac-
6FP or MR1-5-OP-RU tetramer. In the next three panels, CD3+ Vα7.2+ MR1-5-OP-RU tetramer+ 
MAIT cells were analyzed for CD4, CD8, CD161, CD218 and CD27 expression. (b) Graph depicts 
percentage MR1-5-OP-RU tetramer+ cells of total Vα7.2+ population in thymus, cord blood, young 
and adult peripheral blood. Data shows 9 samples for cord, young and adult blood and 12 thymus 
samples. (c) Percentages of CD161-CD218- subset of total MAIT cells in thymus, cord blood, 
young and adult peripheral blood. Sample size as per (b).  (d) Percentages of CD4+CD8+, 
CD4+CD8-, and CD4-CD8+ MAIT cells in human thymus and young peripheral blood. Donor 
matched samples are indicated with a line. Data shows 9 samples for young peripheral blood and 12 
thymus samples *<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. (e) Graph 
depicts percentage MR1-5-OP-RU tetramer+ cells of total Vα7.2+ population in donor matched 
thymus and young peripheral blood samples. (f) Percentages of CD27-CD161-, CD27+CD161-, and 
CD161+ MAIT cells in 5 thymii, 4 cord bloods, 4 young and 5 adult peripheral blood. 
 
Figure 8. Phenotypic, transcriptional and functional analysis of human MR1-5-OP-RU+ 
MAIT cells from thymii, cord bloods, young and adult peripheral blood 
(a) Expressions of CD4/CD8 co-receptors, CD8a/CD8β, CCR5/CCR6 on stage 1 (CD161-CD27-) 
cells in blue, stage 2 (CD161-CD27+) cells in green and stage 3 cells  (CD161+CD27-/+) in red, 
young peripheral blood MAIT cells in yellow, and adult peripheral blood MAIT cells in purple. 
Data are representative of 6 thymic/young blood donor samples, and 5 adult donor samples. (b) 
PLZF, RORγT and Tbet expression on thymic stage 1 (CD161-CD27-) cells in blue, stage 2 
(CD161-CD27+) cells in green, stage 3 cells MAIT (CD161+CD27-/+) in red, matched blood MAIT 
cells in yellow, and double positive (DP) thymocytes in black. Data are representative of 5 thymic 
and young blood donor samples. (c) MR1-5-OP-RU enriched human thymii and matched peripheral 
blood were stimulated for 4h in presence of PMA/ionomycin, labeled with MR1-5-OP-RU tetramer 
and surface antibodies, fixed and permeabilized and then stained with anti-IFN-γ or TNFα. Data are 
representative of 4 independent experiments with 4 thymic and young blood donor samples. (d) 
Percentages of stage 1, stage 2 and stage 3 MAIT cells producing IFN-γ and/or TNFα in enriched 
human thymii and matched peripheral blood. Sample size as per c.  
 
 
 
Supplementary Table 1. TCR sequences of mouse MAIT cell subsets 
MR1-5-OP-RU tetramer+ stage 1 CD24+CD44- and stage 3 CD24-CD44+ MAIT cells were sorted as 
single cells and their TCRα and β chains were determined using single cell TCR sequencing. X 
defines undetermined amino acid.  
 
Supplementary Table 2. Phenotypic characteristics of stage 1 and stage 3 MAIT cells in mice 
Stage 1 and stage 3 MAIT cells were labelled with antibodies for a panel of phenotypic markers and 
analysed by flow cytometry 
 
Supplementary Figure 1. Thymic MAIT cell subsets in Vα19 transgenic mice 
Flow cytometry analysis of MR1-5-OP-RU tetramer reactive MAIT cells for expression of CD4, 
CD8, CD24 and CD44 in adult Vα19 transgenic mouse thymus. Data are representative of 3 
independent experiments.  
 
Supplementary Figure 2. RORγT expression in MAIT cell subsets in RORγT-GFP reporter 
mice 
CD24, CD44, and GFP expression on MAIT cells from enriched RORγT-GFP reporter mouse 
thymus. Data are representative of 3-pooled mouse thymii from 2 independent experiments.  
 
Supplementary Figure 3. MAIT cell numbers in IL-18 KO mice and IL-18Rα KO mice 
(a) Analysis of MAIT cells from pooled MR1-5-OP-RU enriched thymii, whole spleen and lymph 
nodes from C57BL/6 WT and IL-18KO (KO) mice. Cells were examined for CD24 and CD44 
expression using flow cytometry. Data are representative of 3 independent experiments with a total 
of 12 mice per group. (b) Absolute numbers and percentage MAIT cells of TCRβ+ cells in 
individual thymus, spleen and lymph nodes of WT and IL-18KO (KO) mice were graphed. (c) 
Analysis of MAIT from pooled MR1-5-OP-RU enriched thymii, whole spleen and lymph nodes 
from C57BL/6 WT and IL-18RαKO (KO) mice. Cells were examined for CD24 and CD44 
expression using flow cytometry. Data are representative of 2 independent experiments with a total 
of 10 mice per group. (d) Absolute numbers and percentage CD44+ of MAIT cells recovered per 
thymus post MR1-5-OP-RU enrichment from WT and KO mice were graphed. Absolute numbers 
and percentage MAIT cells of TCRβ+ cells in individual spleen and lymph nodes of WT and IL-
18KO (KO) mice were graphed. Bars depict mean ± SEM, data are representative of 3 independent 
experiments with a combined total of 12 mice per group; n.s. = non-significant, *P<0.1 **P<0.01 
***P<0.001 using a Mann-Whitney rank sum U test. (e) Representative analysis of NKT cells from 
thymus of WT and IL-18KO (KO) via flow cytometry. Sample size as per (a). (f) Absolute numbers 
and percentage NKT cells of TCRβ+ cells were graphed. (g) Analysis of CD218 (IL-18Rα) 
expression on MR1-5-OP-RU+ TCRβ+ cells in the thymus of WT and PLZF KO mice. 
 
Supplementary Figure 4. Mouse MAIT cells develop and are present in the periphery of µMT 
mice. 
(a) Analysis of MAIT from pooled MR1-5-OP-RU enriched thymii, whole spleen and lymph nodes 
from C57BL/6 WT and B-cell deficient (µMT) mice. Cells were examined for CD24 and CD44 
expression using flow cytometry. Data are representative of 2 independent experiments with a total 
of 6 mice per group. (b) Absolute numbers of lymphocytes in WT and µMT mice thymus, spleen 
and lymph nodes were graphed in the first column. Absolute numbers and percentage CD44+ of 
MAIT cells recovered per thymus post MR1-5-OP-RU enrichment from WT and µMT mice were 
graphed. Absolute numbers and percentage MAIT cells of TCRβ+ cells in spleen and lymph nodes 
of WT and KO mice were graphed. Bars depict mean ± SEM, data are representative of 2 
independent experiments with a combined total of 6 mice per group *P<0.1 **P<0.01 ***P<0.001 
using a Mann-Whitney rank sum U test. 
 
Supplementary Figure 5. Schematic of the three MAIT cell development stages. 
Mouse and Human MAIT cell development can be defined by three separate stages as shown. 
These are regulated at specific control points. 
 
(data not shown) Supplementary Figure. IL-37 Transgenic Figure 
(a) Analysis of MAIT from pooled MR1-5-OP-RU enriched thymii, whole spleen and lymph nodes 
from C57BL/6 WT and IL-37 Tg (Transgenic) mice. Cells were examined for CD24 and CD44 
expression using flow cytometry. Data are representative of 1 independent experiment with a total 
of 5 mice per group. (b) Absolute numbers and percentage MAIT cells of TCRβ+ cells in individual 
thymus, spleen and lymph nodes of WT and IL-18KO (KO) mice were graphed. Bars depict mean ± 
SEM, data are representative of 1 independent experiment with a combined total of 5 mice per 
group *P<0.1 **P<0.01 ***P<0.001 using a Mann-Whitney rank sum U test. 
 
 
 
 
Methods 
Mice.  
C57BL/6 (B6) mice, MR1 KO mice, Va19 TCR transgenic Ca-/- mice, µMT mice (all on a 
C57BL/6 background), and CD1d KO mice on a C57BL/6 and BALB/C background were bred in 
house at the Department of Microbiology and Immunology Animal House, University of 
Melbourne. PLZF KO mice were generated and bred in house at the John Curtin School of Medical 
Research as previously described11. All procedures using mice were approved by the University of 
Melbourne Animal Ethics Committee or the Australian National University Animal 
Experimentation Ethics Committee. Single cell suspensions from mouse thymus, spleen, lung and 
inguinal lymph nodes were prepared as previously described (Rahimpour et al., 2015). Still need to 
add IL-18, IL-18R KO, Drosha and germ free mice. 
 
Human blood and tissue  
Adult peripheral human blood samples were obtained from the Australian Red Cross Blood Service 
under agreement number 13-04VIC-07. Young human peripheral blood samples and matching 
thymus (donors ranged from 2 days to 12 years of age) were obtained from the Royal Children’s 
Hospital (RCH), Victoria, Australia. Umbilical cord blood samples were obtained from the Mercy 
Hospital for Women, Victoria, Australia. Experiments were conducted in accordance with 
University of Melbourne Human Research and Ethics committee guidelines (reference numbers 
1035100 and 1443540), Mercy Health Human Research Ethics Committee Approval (reference 
number R14/25) and RCH Human Research Ethics Committee Approval (reference number 24131 
G). Blood mononuclear cells were isolated by Ficoll-Paque PlusTM density gradient centrifugation 
(GE Healthcare). Donor thymii were cut into small pieces and passed through a 70 micron cell 
strainer into ice-cold RPMI-1640 medium containing 2mM EDTA before being washed into PBS + 
2% Fetal Calf Serum (FACS buffer). 
 
Magnetic bead enrichment of thymic MAIT cells. 
Mouse and human MR1 tetramers were generated and biotinylated as previously described2, 20. 
Biotinylated MR1-5-OP-RU or control or Ac-6FP monomers were tetramerized with streptavidin 
conjugated to either PE (SA-PE) (BD Pharmingen) or Brilliant Violet 421 (SA-BV) (Biolegend). 
Single cell suspensions of mouse thymus were prepared and stained with PE-mouse MR1-5-OP-RU 
tetramers prior to magnetic bead enrichment using anti-PE microbeads as per manufacturer’s 
instructions (Miltenyi Biotec). One independent enriched sample represents 3 pooled thymii unless 
specified. Single cell suspensions of human thymus were enriched for Va7.2+ cells by staining for 
Va7.2-PE antibody, followed by magnetic bead enrichment using anti-PE microbeads (Miltenyi 
Biotec). 
 
Single cell TCR sequencing. 
MR1-5-OP-RU tetramer+ cells were single cell sorted based on CD24 and CD44 expression and 
cDNA prepared using SuperScript VILO (Invitrogen) as per manufacturer's instructions. 
Transcripts encoding different Va and Vb genes were amplified using multiplex nested PCR as 
previously described45. PCR products were separated using a 1.5% agarose gel and sequenced by 
The Molecular Diagnostics Unit, University of Melbourne.  
 
Flow Cytometry. 
Mouse and human cells were stained with viability dye 7-aminoactinomycin D (7-AAD; Sigma) 
and the following cell surface antibodies. Mouse: TCRβ (H57-597, BD Pharmingen), CD4 (RM4-5, 
Biolegend), CD8a (53-6.7, BD Pharmingen), CD16/32 (2.4G2, produced in-house), CD24 (M1/69, 
BD Pharmingen), CD44 (IM7, BD Pharmingen, eBioscience), CD62L (MEL-14, eBioscience), 
CD69 (H1.2F3, eBioscience), CD103 (2E7, Biolegend), CD127 (IL-7R A7R34, eBioscience), 
CD218 (IL-18Rα BG, Biolegend), NK1.1 (PK136, BD Pharmingen) and B220 (RA3-6B2, BD 
Pharmingen). Human: CD3ε (UCHT1, BD Biosciences), CD4 (OKT4, Biolegend), CD8α (SK1 
Biolegend), CD8β (H35-17.2, BD Pharmingen), CD14 (M5E2, Biolegend), CD19 (HIB19, 
Biolegend), CD27 (O323, Biolegend), CD161 (HP-3G10, Biolegend), CCR5 (HEK/1/85a, 
Biolegend), CCR6 (G034E3, Biolegend), IL-18Rα (H44, Biolegend) and Vα7.2 (3C10, Biolegend). 
Cells were analysed using a BD LSR Fortessa equipped with a 561nm yellow-green laser and data 
processed using FlowJo software (Treestar). Mouse cells are gated on B220- lymphocytes and 
human cells on CD14- CD19- lymphocytes after dead cell and doublet exclusion. Mouse MAIT 
cells were sorted using a BD FACSAriaIII cell sorter. 
 
Intracellular cytokine and intracellular transcription factor staining. 
Briefly, magnetic bead enriched MR1-5-OP-RU tetramer+ cells from mouse thymus were 
stimulated for 4h with PMA (10 ng/ml) and ionomycin (1 µg/ml) in the presence of GolgiStop (BD 
Biosciences). Surface staining of the cells was then performed, before the cells were fixed and 
permeabilized using BD Cytofix/Cytoperm kit (BD Biosciences) as per manufacturer’s instructions. 
Cells were then stained for intracellular cytokines with anti-IFN-γ (mouse: XMG1.2, BD 
Pharmingen, human: B27, BD Pharmingen), anti-IL-17A (mouse: TC11-18H10, BD Pharmingen) 
and anti-TNFα (human: MAb11, BD Pharmingen) prior to flow cytometric analysis. Transcription 
factors were assessed by staining with antibodies: PLZF (Mags.21F7, eBioscience), T-bet 
(eBio4B10, eBioscience) and RORγT (B2D, eBioscience) after the cells were surface-stained and 
permeabilized with the eBioscience Foxp3 Fixation/Permeabilization kit, according to the 
manufacturer’s instructions.  
 
OP9 co-culture differentiation assay. 
To verify the precursor-product relationship of mouse MAIT cells, an adaptation of the OP9 co-
culture protocol previously described23 was used. Briefly, OP9 cells were plated in 96 well plates 
using DMEM media supplemented with 10% (v/v) Fetal Calf Serum (FCS), 1x GlutaMAXTM 
(2mM L-Glutamine, Gibco) 15mM HEPES (Gibco), 0.1mM NEAA (non-essential amino acids, 
Invitrogen), 100U/ml penicillin (sodium salt, Gibco), 1mM sodium pyruvate (Invitrogen), 100µg/ml 
streptomycin sulfate (Gibco) and 50µM 2-mercaptoethanol (Sigma). 1x104 sorted MAIT cells from 
various stages (Stage 1, 2 and 3) were cultured in the presence or absence of OP9 cells with 
identical media supplemented with mouse IL-2 (50ng/ml, Peprotech). MR1 blocking antibody 
(clone 8F2.F9)46 was added at 10ug/ml. MAIT cells were harvested after 5 days, stained with 
antibodies and analysed by flow cytometry.  
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